BGB-102

Description: BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular degeneration and diseases associated with genetic disorders and malformations. Target: Src, EGFR, FLT, VEGFR. Smiles: BrC1=CC=C2C(=C1)NC=3N=CN=C4C=C(OC)C(OCCCCCN(C)C2)=CC43. References: Gijsen M, et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 2010 Dec 21,8(12):e1000563.